as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹287.4
Change
-2.35 (-0.81%)
Open
₹292.35
Prev. Close
₹289.75
Day High
₹295.0
Day Low
₹285.0
Volume Analysis
Traded
2,608
Delivered
61,303
Delivery %
47.66%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •Low return on equity (3.95%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (43/100)
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹303.26 | ₹299.13 | ₹293.26 | ₹289.13 | ₹283.26 | ₹279.13 | ₹273.26 |
| Fibonacci | ₹299.13 | ₹295.31 | ₹292.95 | ₹289.13 | ₹285.31 | ₹282.95 | ₹279.13 |
| Camarilla | ₹290.15 | ₹289.23 | ₹288.32 | ₹289.13 | ₹286.48 | ₹285.57 | ₹284.65 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-24.68%
1 Week
+5.74%
1 Month
+8.64%
3 Months
+17.52%
6 Months
+6.62%
1 Year
-28.92%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹203.97
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
8.52%
Net margin 5.71% × asset turnover 0.95x × equity multiplier 1.57x
Company Overview
Sector
Healthcare
Market Cap
₹407 Cr
P/E (TTM)
35.2
ROE
3.95%
Book Value
₹208.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Medicamen Biotech Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 43/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (3.95%); promoter holding is falling. FII holding has been rising.
TopFund Score — Fundamentals Quality
43/100 — WeakData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Promoter holding has increased by 2.11% over last quarter.
- −The company has delivered a poor sales growth of 11.9% over past five years.
- −Company has a low return on equity of 4.23% over last 3 years.
- −Dividend payout has been low at 14.5% of profits over last 3 years
- −Company has high debtors of 151 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Certificate under Regulation 74 (5) of SEBI (DP) Regulation 2018- September 30, 2026
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 44 | 47 | 47 | 43 | 45 | 45 | 30 | 43 | 47 | 47 | 61 | 48 | 55 |
| Expenses + | 39 | 42 | 42 | 40 | 39 | 38 | 31 | 38 | 42 | 43 | 55 | 44 | 46 |
| Operating Profit | 5 | 5 | 6 | 3 | 5 | 7 | -2 | 5 | 5 | 4 | 5 | 4 | 9 |
| OPM % | 10.68% | 10.54% | 12.15% | 8.01% | 11.87% | 14.86% | -5.44% | 10.71% | 10.94% | 9.34% | 8.95% | 9.04% | 15.83% |
| Other Income + | 1 | 1 | 1 | 1 | 0 | 0 | 5 | 0 | 0 | 1 | 2 | 1 | 0 |
| Interest | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 2 |
| Depreciation | 2 | 2 | 2 | 2 | 3 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 2 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 3 | 2 | 5 | 3 | 5 |
| Tax % | 39.68% | 38.11% | 22.93% | 48.72% | 53.85% | 24.74% | 25.3% | 24.88% | 21.27% | 22.27% | 12.06% | 28.4% | 19.53% |
| Net Profit + | 1 | 2 | 2 | 1 | 1 | 3 | 2 | 2 | 2 | 2 | 4 | 2 | 4 |
| EPS in Rs | 1 | 2 | 2 | 1 | 1 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 30 | 31 | 22 | 3 | 3 | -3 | -37 | 0 | 5 | 4 | 105 | 11 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 78 | 67 | 82 | 112 | 123 | 125 | 113 | 115 | 141 | 179 | 163 | 198 | 210 |
| Expenses + | 73 | 62 | 71 | 95 | 105 | 106 | 93 | 91 | 117 | 156 | 148 | 177 | 187 |
| Operating Profit | 5 | 6 | 12 | 17 | 17 | 20 | 20 | 24 | 24 | 24 | 14 | 21 | 23 |
| OPM % | 6.0% | 8.0% | 14.0% | 15.0% | 14.0% | 16.0% | 17.0% | 21.0% | 17.0% | 13.0% | 9.0% | 10.0% | 11.0% |
| Other Income + | 1 | 1 | 0 | 2 | 4 | 2 | 1 | 2 | 2 | 2 | 6 | 3 | 3 |
| Interest | 4 | 4 | 4 | 3 | 1 | 1 | 2 | 2 | 3 | 6 | 4 | 5 | 4 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 6 | 7 | 7 | 7 | 7 |
| Profit before tax | 0 | 1 | 6 | 14 | 18 | 18 | 16 | 18 | 17 | 13 | 10 | 12 | 15 |
| Tax % | -267.0% | 32.0% | 19.0% | 27.0% | 31.0% | 26.0% | 26.0% | 18.0% | 14.0% | 27.0% | 34.0% | 18.0% | — |
| Net Profit + | 0 | 0 | 5 | 10 | 12 | 13 | 12 | 15 | 15 | 9 | 7 | 10 | 12 |
| EPS in Rs | 0 | 0 | 5 | 9 | 10 | 11 | 10 | 12 | 12 | 9 | 6 | 7 | 9 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 12.0% | 10.0% | 5.0% | 10.0% | 8.0% | 9.0% | 12.0% | 18.0% | 14.0% | — |
| Sales growth | 6 | -14 | 23 | 35 | — | 2 | -10 | 2 | 22 | 27 | -9 | 22 | 27 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 8 | 8 | 16 | 63 | 75 | 109 | 121 | 134 | 181 | 194 | 200 | 262 | 268 |
| Borrowings + | 21 | 19 | 18 | 14 | 12 | 11 | 19 | 26 | 26 | 31 | 34 | 49 | 41 |
| Other Liabilities + | 31 | 23 | 29 | 28 | 38 | 49 | 42 | 53 | 59 | 56 | 50 | 47 | 37 |
| Total Liabilities | 69 | 60 | 73 | 118 | 137 | 181 | 194 | 226 | 279 | 295 | 297 | 372 | 360 |
| Fixed Assets + | 20 | 19 | 19 | 25 | 24 | 34 | 90 | 92 | 93 | 92 | 87 | 85 | 82 |
| CWIP | 0 | 0 | 0 | 0 | 15 | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 49 | 41 | 54 | 92 | 97 | 107 | 104 | 133 | 186 | 203 | 210 | 287 | 278 |
| Total Assets | 69 | 60 | 73 | 118 | 137 | 181 | 194 | 226 | 279 | 295 | 297 | 372 | 360 |
| Equity Capital | 10 | 10 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 14 | 14 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -3 | 6 | 4 | -5 | 4 | 13 | 13 | 4 | -6 | -7 | -8 | -33 |
| Cash from Investing Activity + | 0 | -1 | -2 | -8 | -15 | -37 | -18 | -8 | -6 | -6 | -1 | -3 |
| Cash from Financing Activity + | 3 | -5 | -1 | 33 | -4 | 19 | 6 | 4 | 29 | 6 | -1 | 64 |
| Net Cash Flow | 0 | 0 | 0 | 20 | -14 | -5 | 1 | 0 | 17 | -6 | -11 | 28 |
| Free Cash Flow | -3 | 5 | 1 | -14 | -11 | -25 | -5 | -4 | -13 | -13 | -10 | -38 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -65 | 112 | 31 | -29 | 48 | 88 | 88 | 30 | -13 | -16 | -47 | -150 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Oct 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 55.69% | 55.78% | 55.79% | 56.04% | 55.99% | 58.83% | 58.84% | 59.02% | 59.39% | 59.01% | 55.0% | 53.01% |
| Promoters | 43.21% | 42.99% | 42.99% | 42.99% | 43.16% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% | 42.57% |
| Government | 0.0% | 0.0% | 0.0% | 0.06% | 0.06% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% |
| FII | 0.12% | 0.06% | 0.06% | 0.06% | 0.12% | 0.0% | 0.05% | 0.02% | 0.1% | 0.07% | 4.49% | 4.35% |
| DII | 0.99% | 1.17% | 1.17% | 0.87% | 0.69% | 0.64% | 0.59% | 0.44% | 0.0% | 0.4% | 0.0% | 0.0% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Medicamen Biotech Limited (this stock) | 407 | 35.2 | 1.39 | 3.95% |
| Qms Medical Allied S Ltd | 336 | 31.3 | 3.23 | 10.4% |
| Lyka Labs Ltd. | 328 | — | 3.39 | -10.2% |
| Haleos Labs Limited | 494 | 38.1 | 2.25 | 8.44% |
| Ambalal Sarabhai Ent L | 304 | 19.6 | 1.86 | 12.4% |
| Nureca Limited | 293 | 61.4 | 1.56 | 1.12% |
| Valiant Laboratories Ltd | 570 | 35.2 | 1.72 | -2.55% |
Which Mutual Funds Hold Medicamen Biotech Limited?
Frequently Asked Questions about Medicamen Biotech Limited
Medicamen Biotech Limited (MEDICAMEQ) closed at ₹287.4 on NSE on 19 November 2026, down 2.35 (0.81%) from the previous close.
Medicamen Biotech Limited trades on the NSE (National Stock Exchange of India) under the symbol MEDICAMEQ.
Medicamen Biotech Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 35.2.
Medicamen Biotech Limited has a dividend yield of 0.35%.
Medicamen Biotech Limited's 52-week high is ₹454.0 and its 52-week low is ₹210.0.
Medicamen Biotech Limited has a market capitalisation of ₹407 crore.
Medicamen Biotech Limited has a TopFund Quality Score of 43/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Medicamen Biotech Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.